Calyxt (CLXT) Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Calyxt in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CLXT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CLXT, but not buy additional shares or sell existing shares.
View CLXT analyst ratings or view top-rated stocks.

Calyxt's stock was trading at $1.4750 at the start of the year. Since then, CLXT shares have increased by 265.4% and is now trading at $5.39.
View the best growth stocks for 2023 here.

Calyxt saw a increase in short interest in May. As of May 15th, there was short interest totaling 118,100 shares, an increase of 42.1% from the April 30th total of 83,100 shares. Based on an average trading volume of 35,200 shares, the days-to-cover ratio is presently 3.4 days. Approximately 5.1% of the company's shares are sold short.
View Calyxt's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our CLXT earnings forecast.

Calyxt, Inc. (NASDAQ:CLXT) released its quarterly earnings results on Monday, May, 1st. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.60) by $0.49. The company had revenue of $0.04 million for the quarter. Calyxt had a negative net margin of 9,979.64% and a negative trailing twelve-month return on equity of 259.69%.

Shares of Calyxt reverse split on the morning of Tuesday, April 25th 2023. The 1-10 reverse split was announced on Tuesday, April 25th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Calyxt investors own include Cellectis (CLLS), Molecular Templates (MTEM), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Corbus Pharmaceuticals (CRBP), Cypress Semiconductor (CY), Dynavax Technologies (DVAX), GW Pharmaceuticals (GWPH), Iovance Biotherapeutics (IOVA) and Invitae (NVTA).

(CLXT) raised $101 million in an initial public offering on Thursday, July 20th 2017. The company issued 6,100,000 shares at $15.00-$18.00 per share. Citigroup, Credit Suisse, JefferiesWells and Fargo Securities acted as the underwriters for the IPO and BMO Capital Markets and Ladenburg Thalmann were co-managers.

Calyxt trades on the NASDAQ under the ticker symbol "CLXT."

Calyxt's stock is owned by many different institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (10.86%) and BlackRock Inc. (2.95%). Insiders that own company stock include Andre Choulika, Christopher J Neugent, Daniel F Voytas, James Blome, Michael A Carr, Philippe Dumont, Travis Frey, William Koschak and Yves J Ribeill.
View institutional ownership trends.

Shares of CLXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CLXT stock can currently be purchased for approximately $5.39.

Calyxt (NASDAQ:CLXT) has a market capitalization of $26.79 million and generates $160,000.00 in revenue each year. The company earns $-16,890,000.00 in net income (profit) each year or ($3.49) on an earnings per share basis.

Calyxt's mailing address is 2800 MOUNT RIDGE ROAD, ROSEVILLE MN, 55113. The official website for the company is www.calyxt.com. The company can be reached via phone at (651) 683-2807 or via email at clxt@mzgroup.us.